Stay up to date with news and events
PROOF-HD study of pridopidine ends with negative result
April 26, 2023
Top line results of the PROOF-HD study, run by Prilenia Therapeutics and testing pridopidine, have been announced at the American Academy of Neurology convention. Sadly…
Astrocytes: The new star in HD research?
April 21, 2023
The most obvious changes related to Huntington’s disease (HD) happen to neurons, the nervous system’s messenger cells that send and receive information throughout the brain…
Hunting for balance: how the huntingtin protein compensates in HD
April 6, 2023
A group led by Dr. Sandrine Humbert from the French National Institute for Health and Medical Research published new work in the prestigious journal Science….
Roche Phase II GENERATION HD2 study underway
February 16, 2023
Roche released a community letter last month, detailing how their Phase II clinical trial to study the huntingtin-lowering drug, tominersen, is now underway. Learn more…
Disappointing news from Novartis about branaplam and the VIBRANT-HD trial
December 9, 2022
The pharmaceutical company Novartis has released a community update which announces that they are ending development of branaplam, a huntingtin lowering drug, for possible treatment…